Search Results - soheil+meshinchi

2 Results

Sort By:

Therapeutic targeting PRAME with mTCRCAR T cells 1 in Acute Myeloid Leukemia

TCR mimic CAR T cells targeting PRAME/HLA-A2 Chimeric antigen receptor (CAR) that bind Preferentially Expressed Antigen in Melanoma (PRAME) ALYVDSLFFL (ALY) / HLA-A*0201 (HLA-A2) to treat PRAME-expressing cancers. PRAME is aberrantly expressed in childhood and adult AML and is absent in normal hematopoietic cells, providing an ideal target for...

Published: 10/14/2024 | Updated: 2/28/2023 | Inventor(s): Soheil Meshinchi, Danielle Kirkey, Anisha Loeb, Quy Le

Keywords(s): Immuno Oncology

Category(s): Therapeutic

Mesothelin directed chimeric antigen receptor T cells for treatment of acute myeloid leukemia

Mesothelin-directed CAR T Cells for the Treatment of Acute Myeloid Leukemia CAR T cells targeting mesothelin to treat Leukemia Despite maximally intensive therapy, approximately 40% of patients with acute myeloid leukemia (AML) will relapse. An effective targeted therapy is still needed to save the lives of AML patients. Through computational...

Published: 10/14/2024 | Updated: 1/20/2023 | Inventor(s): Soheil Meshinchi, Quy Le, Rhonda Ries

Keywords(s): Biomarker, Target, Vectors

Category(s): Cell Therapy